Mirikizumab is an anti-IL-23 monoclonal antibody used as a second-line therapy for moderate-to-severe active ulcerative colitis. It inhibits the actions of interleukin-23 (IL-23), a pro-inflammatory cytokine that activates pathways contributing to the development of inflammatory diseases.
- Mechanism
- Curator reviewed · 1 reference
Mirikizumab is a monoclonal antibody directed against the p19 subunit of human interleukin-23 (IL-23). The binding of mirikizumab to its target inhibits the interaction between IL-23 and the IL-23 receptor, thereby normalizing the overproduction of effector cytokines driving the pathogenesis of inflammatory diseases, including ulcerative colitis.
- Primary indication
- Mirikizumab is indicated for the treatment of adult patients with moderate-to-severely active ulcerative colitis.Curator reviewed · 4 structured indications
- Formula / weight
- 147000.0 Da
- First approval
- Canada, 2023 · United States, 2023 · European Union, 2023
- Code names
- LY-3074828
- Brand names
Resolves to
What you can answer from here — as of March 15, 2025
Which drugs share a target with Mirikizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account